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Abstract
Background Ranibizumab, a vascular endothelial growth
factor (VEGF) inhibitor, is used in the treatment of age-
related macular degeneration. Inhibition of VEGF has an
anti-angiogenic action and is associated with thromboge-
nicity, thus, myocardial infarction and ischaemic stroke are
potential side effects of VEGF inhibitors.
Objective Our objective was to assess the association
between use of ranibizumab and risk of hospitalisation for
ischaemic stroke (IS) and myocardial infarction (MI).
Methods The self-controlled case series design was used,
including subjects exposed to ranibizumab (Anatomical
Therapeutic Chemical [ATC] code S01LA04) who were
hospitalized for IS (International Classification of Dis-
eases, tenth edition [ICD-10] code I63) or the combined
endpoint of stroke or transient ischaemic attack (TIA)
(ICD-10 code G45) or MI (ICD-10 code I21) were iden-
tified between August 2007 and March 2013. Rate ratios in
exposed periods compared with unexposed periods were
calculated using conditional Poisson regression.
Results A total of 323 subjects received ranibizumab and
were hospitalized for IS, 490 for IS or TIA, and 391 for MI.
Median period of exposure was 8–9 months with follow-up
times of approximately 2.8 years. No elevated risk of IS
was seen in the 1–30 days post initiation (incidence rate
ratio [IRR] 1.36; 95 % confidence interval [CI] 0.98–1.88);
however, elevated risk was observed for those who
received therapy for 31–60 days (IRR 1.91; 95 % CI
1.13–3.24). Sensitivity analyses adjusting for time-varying
confounders found elevated risk in both the 1–30 days and
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31–60 days periods. Similar results to those for IS were
observed for the combined endpoint of IS or TIA. No
association was seen for MI in either time period
(1–30 days IRR 0.90, 95 % CI 0.65–1.23; 31–60 days IRR
0.98, 95 % CI 0.54–1.79).
Conclusion This case-series analysis suggests an
increased risk of hospitalisation for ischaemic stroke for
patients receiving ranibizumab in the 31–60 days risk
period. Studies with larger populations are required to
confirm the risk in the 1–30 days risk period. No evidence
of increased risk of hospitalisation for MI was observed.
1 Introduction
Ranibizumab, a vascular endothelial growth factor (VEGF)
inhibitor, is used in the treatment of age-related macular
degeneration [1]. VEGF stimulates the production of nitric
oxide, which has multiple vasculoprotective effects,
including vasodilation, antithrombotic activity and angio-
genesis [2]. Inhibition of VEGF has an anti-angiogenic
action and is associated with thrombogenicity, thus, myo-
cardial infarction (MI) and ischaemic stroke (IS) are
potential side effects of VEGF inhibitors [2]. The initial
ranibizumab trials, on which market registration was
granted, highlighted the potential safety issue of throm-
boembolic events. The ANCHOR clinical trial showed a
higher rate of arterio-thromboembolic events in those
receiving 0.5-mg doses of ranibizumab compared with the
0.3-mg dose or verteporfin injection (4.3 % in the 0.5-mg
group vs. 2.2 and 2.1 % in the 0.3-mg and verteporfin
groups, respectively) [3]. The MARINA clinical trial
showed rates of arterio-thromboembolic events were 4.6 %
in those treated with 0.3 or 0.5 mg ranibizumab compared
with 3.8 % in those who received sham injections [4]. A
2009 meta-analysis of the data from the MARINA,
ANCHOR and FOCUS trials pooled data for 859 subjects
treated with ranibizumab (either 0.5 or 0.3 mg) and 454
treated with sham injections. The meta-analysis found an
increased but non-significant risk of cerebrovascular acci-
dent (CVA) in those receiving monthly ranibizumab
injections compared with sham injections (odds ratio [OR]
3.24 [95 % confidence interval (CI) 0.96–10.95]). No
association was observed for MI (OR 0.61 [95 % CI
0.29–1.29]) or the combined endpoint of MI or CVA (OR
1.08 [95 % CI 0.59–1.98]) [5]. Another meta-analysis also
showed no increased risk from trial data when assessing the
combined endpoint of MI and stroke between ranibizumab
and bevacizumab (relative risk [RR] 0.80 [95 % CI
0.30–2.13]) [6]. A 2012 pooled analysis using data from
five trials showed no statistically significant increase in risk
of cerebrovascular events when comparing the different
doses against placebo (ranibizumab 0.5 mg vs. control OR
2.2 [95 % CI 0.8–7.1]; ranibizumab 0.3 mg vs. control OR
1.2 [95 % CI 0.4–4.4]) or against each other (0.5 vs.
0.3 mg OR 1.5 [95 % CI 0.8–3.0]) [7]. However, there was
a sevenfold (OR 7.7 [95 % CI 1.2–177]) increased risk of
stroke with 0.5 mg ranibizumab compared with control in
patients who were at high risk for CVA [7].
A large observational cohort study used administrative
claims data to assess the adverse events of death, haem-
orrhage, MI and stroke associated with VEGF inhibitors. It
involved almost 147,000 subjects and found a reduced risk
of MI but no difference in stroke risk when ranibizumab
was compared with photodynamic therapy, pegatinib or
bevacizumab [8]. Stroke outcomes assessed included the
combined endpoint of haemorrhagic stroke or IS. IS was
not reported separately. A smaller Australian cohort study
involving just under 3,500 patients found an increased risk
of MI in those who attended an eye clinic and received
VEGF inhibitors compared with randomly selected com-
munity controls, but no difference in those who attended
the eye clinic and received photodynamic therapy. No
difference in IS was observed [9]. While the study adjusted
for comorbidities, the community cohort had greater prior
stroke risk, and the extent of residual confounding was
unknown. A nested case–control study compared exposure
to VEGF inhibitors in the 180-day period before incident
stroke or MI. The study included 1,477 stroke cases, 2,229
MI cases and event-free controls matched 5:1. No differ-
ences in exposure to VEGF inhibitors were observed
between cases and controls [10]. An ecological study
assessing trends in stroke rates among the population with
diagnosed retinal disease reported no change in strokes
after introduction of the VEGF inhibitors [11].
The assessment of thromboembolic events as adverse
events of ranibizumab is complicated for two reasons: (1)
stroke and MI are uncommon events, thus large sample sizes
are required to detect differences, and (2) people with
macular degeneration have comorbid conditions that place
them at increased risk of stroke and MI, thus potentially
confounding cohort or case–control studies. To overcome
the potential for this confounding, we chose to assess the
association using the self-controlled case-series method [12,
13]. The main advantage of using this design is that it
minimises confounding because the patient acts as their own
control. The within-person design controls implicitly for
fixed known and unknown confounders, such as background
cerebrovascular risk. Potential confounders that vary over
time, such as age, can be adjusted for within the model. The
design only includes individuals who have the outcome of
interest and who were exposed to the medicine, comparing
time on the medicines with time not exposed. While rani-
bizumab has a suggested monthly dosing schedule, therapy
is often provided intermittently [14, 15], meaning subjects
have both exposed and unexposed time to contribute.
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The aim of this study was to determine the association
between ranibizumab and hospitalisation for IS and MI
using the self-controlled case-series method.
2 Methods
The data source for this study was the Australian Depart-
ment of Veterans’ Affairs (DVA) administrative claims
databases. DVA claims data contain records of prescription
medicines dispensed under the Repatriation Pharmaceuti-
cal Benefits Scheme, medical and allied health services and
hospital admissions provided to clients for whom DVA
pays a subsidy. Across the time period analysed, approxi-
mately 300,000 clients were eligible for inclusion in the
study. A client file is maintained by DVA that includes data
on gender, date of birth, date of death and family status.
We looked at two primary outcomes: (1) hospitalisation
for IS (International Classification of Diseases, tenth edi-
tion [ICD-10] code I63), and (2) combined endpoint of IS
or transient ischaemic attack (TIA) (ICD-10 code G45) and
(3) hospitalisation for MI (ICD-10 code I21). The exposure
of interest for this study was a dispensing of ranibizumab
(Anatomical Therapeutic Chemical [ATC] code
S01LA04). Only those who had been dispensed rani-
bizumab during the study period were included in the study
cohort, as macular degeneration itself is associated with an
increased risk of stroke. To ensure we had ‘new users’, the
study period was the first date that a ranibizumab pre-
scription appeared in the database, 1 August 2007, and the
study end was 31 March 2013. To be eligible for the study,
subjects needed to be aged between 45 and 100 years of
age at 1 August 2007, have at least one prescription
medicine in the 12 months prior to entry into the cohort
and be eligible for all health services subsidised by DVA.
All ranibizumab scripts dispensed during the study
period were obtained for included individuals. Since dos-
age information is not available in the dataset, a patient was
considered ‘exposed’ to ranibizumab for a period of
30 days after the supply date. This assumption is consistent
with its clinical use and duration of therapeutic effect. A
30-day duration of exposure was applied to each dispensing
of ranibizumab. Patients with repeat dispensings within
30 days were considered continuously exposed. If there
was no supply of ranibizumab within the 30 days, the
patient was considered no longer exposed from 30 days
after the last date of supply. The actual date of the injection
was unknown, and this analysis assumes the injection was
the day of supply. Person time was then divided into pre-
and post-exposure risk periods. The time after initiation of
ranibizumab was divided into the following risk periods:
day of supply, 1–30 days, 31–60 days, [60 days and a
wash-out period of 1–30 days starting the day after a
subject was considered to be no longer exposed. Patients
would contribute person time to the 31–60 days risk period
only if they had two dispensings of ranibizumab within
30 days of each other. These risk periods were chosen a
priori to be consistent with dosage recommendation for
ranibizumab, which is one injection per month. Addition-
ally, two consecutive 42-day pre-exposure risk periods
were included prior to the very first supply of ranibizumab
only during the study period. These time periods were
based on rehabilitation times for stroke recovery, which is
a time period in which ranibizumab is unlikely to be used.
All remaining time was considered unexposed to
ranibizumab.
In each risk period, the hospitalisation rate, the cumu-
lative number of hospitalisations divided by the person-
years at risk in that period, was compared with the rate of
hospitalisations in the unexposed risk period. If a subject
was re-hospitalised within 30 days, the subsequent hospi-
talisation(s) were excluded, as they were considered to be
part of the same episode [12]. Incident rate ratios (IRRs)
were calculated using conditional Poisson regression, with
results presented as adjusted rate ratios and 95 % CIs.
Since the self-controlled case-series method controls
implicitly for fixed covariates [12, 13], the primary anal-
yses were adjusted for time-varying age only.
We also performed sensitivity analyses where we (1)
adjusted for potential time-varying confounders, and (2)
included just those patients who survived at least 90 days
after their hospitalisation event. The following time-vary-
ing confounders were considered: number of prescriptions,
number of hospitalisations and number of comorbid con-
ditions (using the validated Rx-Risk-V score [16]), which
were determined annually. A time-varying indicator vari-
able was used for exposure to the following medicines: a
non-steroidal anti-inflammatory drug (NSAID) (M01A), an
antithrombotic (B01A) and an antihypertensive (C09, C08,
C07, C10BX, C03, C02), and adjustment was made for
cancer (hospitalisation ICD code C or D00-D48 or a dis-
pensing of L01 medicine) and renal failure (ICD code N17-
N19) where the indicative hospitalisation or medicine use
occurred in the previous 12 months. Ethics approval was
obtained from the University of South Australia Human
Research Ethics Committee and the DVA Human Research
Ethics Committee. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC, USA).
3 Results
During the study period, 323 subjects received ranibizumab
and experienced an IS, 490 experienced an IS or TIA, and
391 an MI. Characteristics of the study cohort are presented
in Table 1.
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The risk of IS was elevated but not statistically signifi-
cant in the first 30 days after supply (IRR 1.36 [95 % CI
0.98–1.88]); however, the risk was significantly increased
in the 31–60 days after first supply (IRR 1.91 [95 % CI
1.13–3.24]) (Table 2). The risk of stroke for those exposed
for more than 60 days was similar to that for unexposed
patients (IRR 0.73 [95 % CI 0.26–2.07]). For the combined
outcome of IS or TIA, similar results were observed to the
analysis for IS only. No increased risk of MI was observed
in any of the risk periods (Table 2).
The sensitivity analyses, results for the risk of IS were
similar after adjusting for time-varying confounders;
however, the risk was statistically significant in the
1–30 days risk period (IRR 1.38 [95 % CI 1.00–1.91]) and
the 31–60 days risk period (IRR 1.97 [95 % CI
1.16–3.35]). When only those patients who had survived
for at least 90 days after their admission to hospital for the
event of interest were analysed, results were similar, with a
significantly increased risk in the 31–60 days risk period
(IRR 2.10 [95 % CI 1.20–3.69]). No significant association
was found in any of the sensitivity analyses for the out-
come of MI.
4 Discussion
The results of this self-controlled case-series study suggest
an elevated risk of IS in patients who remain on rani-
bizumab therapy between 31 and 60 days post-dispensing.
Adjustment for time-varying confounders found stroke risk
elevated at both 1–30 days and 31–60 days. We found no
evidence of increased risk of MI. No significant increased
risk for IS was detected beyond 60 days of continuous
therapy. Our results differ from those of previous obser-
vational studies, which did not find an increased risk of
stroke [8, 9]; however, our results are consistent with
randomised controlled trial evidence, which found a
statistically non-significant increased risk of stroke and no
increased risk of MI [5].
Observational studies, such as the cohort study design,
have the potential for residual confounding, which is a
particular issue for the population with macular degenera-
tion, as common conditions comorbid to macular degen-
eration increase the risk of MI and stroke independently of
any potential effect of the medicine under study. One of the
advantages of the self-controlled case series design is that it
controls implicitly for patient-specific confounders that do
not vary over time. This means that it is not necessary to
adjust for variables such as gender, frailty or other risk
factors for stroke that are constant over time. Our study
only included people who had received ranibizumab and
who had a stroke, thus limiting confounding due to dif-
ferences in comorbid conditions. Further, our sensitivity
analysis, where we adjusted for comorbidities in a time-
varying manner, did not change the results substantially,
suggesting the design itself adequately controlled for con-
founding. The assessment of the risk of stroke with rani-
bizumab also meets the assumptions of the method, which
are that exposure is intermittent, the outcome is acute and
the occurrence of the outcome, stroke, is unlikely to
influence the exposure, ranibizumab. This means that
hospital events must not increase the probability of death.
We were unable to determine causes of death from our
data, so we could not estimate how many patients died as a
result of stroke. Farrington and Whitaker [17] have shown
that the case-series method may be robust to failure of this
assumption and may result in small negative bias. In this
example, only 11 % of the hospitalisations for stroke
resulted in death at discharge, which suggests that the
results should be robust to the assumption. As a sensitivity
analysis, we included only those patients who had survived
at least 90 days after their stroke, and risk estimates were
similar in this group to those of the primary analysis.
Only one formulation of ranibizumab is subsidised in
Australia, and dosage information is not recorded in the
dataset, thus we were unable to do an analysis by dose. The
initial trials reported a higher risk of stroke with higher
dose of ranibizumab [3]. Another limitation of our study
was that we could not determine whether patients received
injections in one eye only or received bilateral injections.
Bilateral treatment has been reported for between 5 and
20 % of patients [18]. The claims data enabled assessment
of a record of an intravitreal injection, but not the medicine
administered by the injection. Intravitreal injection
(Medicare Benefits Schedule [MBS] code 42740) is not
unique for ranibizumab. Very few of the dispensings of
ranibizumab included in this study could be matched
within a 2-day window to the MBS service claim for in-
travitreal injection. Since we were unable to identify the
actual injection date, our assumed day of exposure, i.e.
Table 1 Characteristics of study subjects
IS IS or TIA MI













Age at first exposure (years) 85 (82–87) 84 (82–87) 84 (82–86)
Age at first hospitalisation
(years)
87 (85–90) 87 (85–90) 87 (84–90)
Male (%) 47 44 55
Data are presented as median (range) unless otherwise indicated
IS ischaemic stroke, MI myocardial infarction, TIA transient ischae-
mic attack
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dispensing date, may be before the medicine was actually
administered. This may partly explain the lower risk of
stroke in the 0–30 days risk period if, in fact, some of the
patients had a delay between dispensing and administra-
tion. We included only those patients who had at least one
dispensing of ranibizumab during the study period. During
the study period, ranibizumab was only subsidised in
Australia for treatment of aged-related macular degenera-
tion as diagnosed by fluorescein angiography. More than
half of the population included in this study had initiated
ranizibumab within 2 years of study entry and are likely to
have pre-existing macular degeneration during this time,
particularly as the treatment was first subsidised in 2007
(study entry date). For some patients, it is possible that
unexposed person-time may include time in which they did
not have macular degeneration and therefore may be at
lower risk of stroke. Including this time may have biased
results away from the null; however, since the study period
is short, this is unlikely to be an issue in this study. Vet-
erans in Australia receive their health services through
Australia’s universal health system. Australia does not
have separate health services for veterans, thus our results
are likely to reflect Australian clinical practice, not veteran-
specific care. Our study was undertaken in the Australian
Table 2 Risk of ischaemic stroke, myocardial infarct, or ischaemic stroke or transient ischaemic attack before and after ranibizumab supply
Risk periods N Person-years Rate per 10 years IRRa IRRb IRRc
Hospitalisation for ischaemic stroke
Unexposed 194 1023 1.94 (1.67–2.26) 1.00 1.00 1.00
Pre 43–84 days 3 31 0.95 (0.30–2.94) 0.49 (0.16–1.53) 0.51 (0.16–1.60) 0.61 (0.19–1.91)
Pre 1–42 days 5 35 1.43 (0.59–3.45) 0.74 (0.30–1.80) 0.76 (0.31–1.87) 0.92 (0.38–2.25)
Same day 2 8 2.37 (0.59–9.51) 1.22 (0.30–4.95) 1.25 (0.31–5.08) 0.77 (0.11–5.54)
Post 1–30 days 65 239 2.64 (2.02–3.46) 1.36 (0.98–1.88) 1.38 (1.00–1.91) 1.32 (0.92–1.90)
Post 31–60 days 17 45 3.71 (2.26–6.10) 1.91 (1.13–3.24) 1.97 (1.16–3.35) 2.10 (1.20–3.69)
Post [60 days 4 28 1.43 (0.52–3.95) 0.73 (0.26–2.07) 0.81 (0.29–2.29) 0.66 (0.20–2.15)
Wash-out period 33 164 1.90 (1.32–2.72) 0.98 (0.65–1.46) 0.99 (0.66–1.49) 1.04 (0.67–1.62)
Hospitalisation for ischaemic stroke or transient ischaemic attack
Unexposed 291 1584 1.90 (1.68–2.15) 1.00 1.00 1.00
Pre 43–84 days 5 48 1.05 (0.43–2.52) 0.55 (0.23–1.34) 0.57 (0.23–1.38) 0.64 (0.26–1.55)
Pre 1–42 days 11 53 2.09 (1.16–3.79) 1.10 (0.60–2.02) 1.12 (0.61–2.05) 1.28 (0.70–2.36)
Same day 4 13 3.04 (1.14–8.14) 1.60 (0.59–4.33) 1.66 (0.61–4.48) 1.41 (0.45–4.43)
Post 1–30 days 94 387 2.46 (1.97–3.06) 1.29 (0.99–1.69) 1.34 (1.02–1.74) 1.29 (0.97–1.72)
Post 31–60 days 27 76 3.64 (2.46–5.40) 1.92 (1.26–2.92) 1.96 (1.29–2.99) 2.05 (1.33–3.18)
Post [60 days 5 43 1.17 (0.48–2.88) 0.62 (0.25–1.54) 0.66 (0.27–1.65) 0.57 (0.20–1.56)
Wash-out period 53 264 1.98 (1.49–2.63) 1.04 (0.76–1.44) 1.07 (0.78–1.48) 1.11 (0.79–1.56)
Hospitalisation for myocardial infarction
Unexposed 254 1275 2.17 (1.90–2.47) 1.00 1.00 1.00
Pre 43–84 days 7 39 1.78 (0.84–3.75) 0.82 (0.39–1.75) 0.87 (0.41–1.85) 0.99 (0.46–2.10)
Pre 1–42 days 5 43 1.13 (0.47–2.72) 0.52 (0.21–1.27) 0.54 (0.22–1.31) 0.64 (0.26–1.55)
Same day 5 10 4.87 (2.02–11.77) 2.25 (0.92–5.51) 2.22 (0.91–5.46) 2.21 (0.81–6.01)
Post 1–30 days 58 298 1.94 (1.48–2.56) 0.90 (0.65–1.23) 0.88 (0.64–1.21) 0.97 (0.69–1.37)
Post 31–60 days 12 57 2.13 (1.19–3.80) 0.98 (0.54–1.79) 1.01 (0.55–1.85) 0.91 (0.46–1.82)
Post [60 days 4 30 1.28 (0.46–3.54) 0.59 (0.21–1.65) 0.61 (0.22–1.70) 0.75 (0.27–2.12)
Wash-out period 46 201 2.28 (1.68–3.09) 1.05 (0.74–1.48) 1.01 (0.71–1.43) 0.94 (0.64–1.40)
Figures in parentheses are 95 % confidence intervals
ICD International Classification of Diseases, IRR incidence rate ratio
 Statistically significant
a Adjusted for age
b Adjusted for age, number of prescriptions, number of hospitalisations and number of comorbid conditions (using the validated Rx-Risk-V
score [16]), which were determined annually. A time-varying indicator variable was used for exposure to the following medicines: a non-
steroidal anti-inflammatory drug (M01A), an antithrombotic (B01A) and an antihypertensive (C09, C08, C07, C10BX, C03, C02), and
adjustment was made for cancer (hospitalisation ICD code C or D00–D48 or a dispensing of L01 medicine) and renal failure (ICD code N17–
N19), where the indicative hospitalisation or medicine use occurred in the previous 12 months
c Analysis in only those patients who survived at least 90 days after their hospitalisation event
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veteran population, which is an elderly population and,
whilst the results are likely to be generalizable to other
elderly populations, the applicability of our results to
younger individuals is unknown. Analysis of data on 4,444
patients enrolled in European registries of macular degen-
eration reported an average age of patients of 78–79 years
[18], which is slightly younger than our population. While
the risk of IS was significantly increased in the 31–60 days
risk period, the number of stroke events was only 17. This
suggests that the absolute risk of IS is low. In the primary
analysis, we included only those patients who had an IS
hospitalisation and were dispensed ranibizumab. A total of
7,898 patients had at least one ranibizumab dispensing
during the study period, equating to rates in the population
with macular degeneration of 4 per 100 for IS, 6.2 per 100
for IS or TIA and 5.0 for MI. This is consistent with studies
showing elevated stroke risk in those with macular
degeneration of 1.5 times that of the general population
[19], which equates to approximately 2.5 % in the general
population over 85 years [20].
5 Conclusion
This self-controlled case-series analysis suggests an
increased risk of IS with ranibizumab in the 31–60 days
risk period. Studies with larger populations are necessary to
confirm the risk in the 1–30 days period. We found no
evidence of increased risk of MI. Our results suggest that
prescribers should be vigilant for stroke risk in their
patients.
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